20 June 2025 - A major shift in cancer treatment will be publicly funded and is set to dramatically increase the survival rates of patients with melanoma, paving the way for a revolution in how other cancers are dealt with.

The pre-surgery use of ­combination immunotherapy for high-risk melanoma, a strategy that will now be publicly funded for all Stage 3 patients, is being ­described as “a revolution in cancer therapy” and is set be replicated across the globe as well as transforming the treatment of a suite of other cancers.

Read The Australian article